Trial Profile
A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects with Advanced Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs SRA 737 (Primary)
- Indications Anal cancer; Colorectal cancer; Head and neck cancer; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Sponsors Sierra Oncology
- 29 Apr 2023 Results published in the British Journal of Cancer
- 28 Nov 2019 Status changed from active, no longer recruiting to completed.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology